A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis

Puopolo, Anthony; Boice, Judith A.; Fidelholtz, James; Littlejohn, Thomas; Miranda, Pedro; Berrocal, A.; Ko, A.; Cichanowitz, N.; Reicin, Alise

doi:10.1016/j.joca.2007.05.022

Cited by 52 publications

(53 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, the etoricoxib 30 and 60 mg doses have shown efficacy in osteoarthritis patients with higher doses not providing additional analgesic benefit. [20][21][22] In rheumatoid arthritis, a condition associated with a higher level of inflammation compared with osteoarthritis, the 90 mg dose has been shown to be the maximal dose of etoricoxib with lower doses not providing adequate analgesic effect alone. 20,23,24 Therefore, it is possible that the inflammatory process associated with postoperative dental pain designs is limited versus a more traumatic surgical setting.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Dose Range of Etoricoxib in an Acute Pain Setting Using the Postoperative Dental Pain Model

Daniels

Bandy

Christensen

et al. 2011

The Clinical Journal of Pain

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the Dose Range of Etoricoxib in an Acute Pain Setting Using the Postoperative Dental Pain Model

Daniels

Bandy

Christensen

et al. 2011

The Clinical Journal of Pain

View full text Add to dashboard Cite

show abstract

“…20 According to several random clinical trials, NSAIDs produced better results with regard to pain when compared to placebo, but with worse results when compared to patients treated with painkillers. 21 NSAIDs operate by inhibiting the synthesis of prostaglandins, which is known as a primary antiinflammatory mechanism; prostaglandins are inflammatory mediators that contribute to pain and inflammation in a process mediated by cyclooxygenase enzymes (COX-1 and COX-2), 19 i.e., they inhibit COX-1 and COX-2. Despite the biomechanical characteristics of the disease, its pathophysiology is caused by an imbalance between the mechanisms of formation and degeneration of the cartilage matrix, being this process regulated by proinflammatory cytokines, such as the interleukin-1 (IL-1), the tumor necrosis factor alpha (TNF-alpha) and proteinases.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the influence of pharmacotherapy on the quality of life of seniors with osteoarthritis

Salvato

Santos

Pires-Oliveira

et al. 2015

Revista Brasileira de Reumatologia (English Edition)

View full text Add to dashboard Cite

r e v b r a s r e u m a t o l . 2 0 1 5;5 5(1):83-88 REVISTA BRASILEIRA DE REUMATOLOGIA w w w . r e u m a t o l o g i a . c o m . b r Brief communication Elderly Functional status Functional disability Quality of life a b s t r a c t Aims: This study aimed to assess the influence of pharmacotherapy on health-related quality of life of elderly with ostheoarthritis. Methods: Longitudinal study involving 91 older adults from both genders (Age: 70.36 ± 5.57 years) from EELO project with self-reported knee or hip ostheoartritis, confirmed by radiographic analysis. Data regarding pharmacotherapy was assessed by a structured questionnaire and the quality of life was analyzed by SF-36 questionnaire at the initial moment and two years thereafter. All domains from quality of life were grouped in physical and mental components for further data analysis. Results: A statistically significant decline in both physical and mental components of quality of life was observed (Wilcoxon test, p < 0.05). However, it was observed a slighted decline in physical components in group treated with chondroitin/glucosamine when compared to other groups, according to Kruskal-Wallis test (p = 0.007). On the other hand, it was not observed any influence of pharmacological treatment on mental components of healthrelated quality of life (p > 0.05). Conclusions: Treatment with condroitin/glucosamin contributes to a lower decline in physical component while it had no influence on mental component of health-related quality of life in older adults with ostheoartritis. 84 r e v b r a s r e u m a t o l . 2 0 1 5;5 5(1):83-88 Análise da influência da farmacoterapia sobre a qualidade de vida em idosos com osteoartritePalavras-chave: Osteoartrite Idoso Funcionalidade Incapacidade funcional Qualidade de vida r e s u m o Objetivos: Analisar a influência da farmacoterapia da osteoartrite na qualidade de vida de idosos. Métodos: Estudo longitudinal, do qual participaram 91 idosos de ambos os gêneros (idade: 70,36 ± 5,57 anos), integrantes do projeto Estudo sobre Envelhecimento e Longevidade (EELO), portadores de osteoartrite de quadril e/ou joelho, confirmada por análise radiográ-fica. Foram levantados dados sobre a farmacoterapia da osteoartrite mediante o uso de questionários estruturados e a qualidade de vida foi analisada pelo questionário SF-36, no momento inicial e dois anos após a coleta de dados. Os diferentes domínios da qualidade de vida foram agrupados em domínios físicos e mentais para posterior análise dos dados. Resultados: Foi observado um declínio estatisticamente significativo tanto nos componentes físicos quanto mentais da qualidade de vida dos indivíduos (teste de Wilcoxon, p < 0,05). Foi observado menor declínio no componente físico da qualidade de vida para os usuários de condroitina/glicosamina em comparação com o grupo tratado com anti-inflamatórios ou não tratado, segundo o teste de Kruskal-Wallis (p = 0,007). Por outro lado, não foi observada influência do tratamento farmacológico sobre o componente mental da qualidade de vida (p > 0,0...

show abstract

“…During 12 weeks of treatment, the risk of GI events was comparable to that found with other comparators (OR=0.38, 95% CrI=0.03∼4.28, P=0.21 compared with placebo, OR=0.94, 95% CrI=0.04∼20.35, P=0.49 with celecoxib and OR=0.49, 95% CrI=0.03∼7.21, P=0.29 with ibuprofen), while the risk of GI events was significantly lower than that found with naproxen (OR=0.18, 95% CrI=0.03∼1.17, P=0.03) ( Figure 4A). Among studies that included patients with OA of the lower extremities and involved treatment of 12 weeks, etoricoxib showed significantly lower risk of GI events compared with naproxen (OR=0.18, 95% CrI=0.01∼2.73, P=0.06), while there was no significant difference compared with placebo, celecoxib, and ibuprofen (OR=0.24, 95% CrI=0.01∼ 6.07, P=0.18 with placebo, OR=0.99, 95% CrI=0.01∼ 162.70, P=0.50 with celecoxib, OR=0.33, 95% CrI=0.00∼ 20.83, P=0.27 with ibuprofen) ( Figure 4B) [26][27][28][29][30]. In analysis according to dose of etoricoxib, 30 mg of etoricoxib showed comparable risk of GI events with celecoxib, ibuprofen and placebo during 12 weeks.…”

Section: Risks Of Gastrointestinal Adverse Events Of Etoricoxibmentioning

confidence: 91%

“…A final 10 studies were included in our study after further reviewing full texts [21][22][23][24][25][26][27][28][29][30]: eight were excluded because they were not RCTs, three were without peer review, seven involved non-OA patients, one did not involve etoricoxib, 16 reported no outcome of interest, two did not utilize adequate comparators, and one was excluded for other reasons (Figure 1). …”

Section: Study Characteristicsmentioning

confidence: 99%

“…The results were consistent when we included studies of patients with OA of the hip or knee joints over a duration of 12 weeks (OR=0.65, 95% CrI=0.08∼4.91, P=0.33 with placebo, OR=0.99, 95% CrI=0.01∼95.15, P=0.50 with celecoxib, OR=0.84, 95% CrI=0.07∼10.07, P=0.44 with ibuprofen, OR=2.11, 95% CrI=0.14∼31.37, P=0.72 with naproxen) ( Figure 3B) [26][27][28][29][30]. In analysis according to dose of etoricoxib, 30 mg of and 60 mg or higher dose of etoricoxib did not increase the risk of CV events compared with comparators during 12 weeks ( Figure 3C).…”

Section: Risk Of Cardiovascular Adverse Events Of Etoricoxibmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis

et al. 2017

View full text Add to dashboard Cite

Objective. To estimate the cardiovascular (CV) and gastrointestinal (GI) risks of etoricoxib in the treatment of osteoarthritis (OA) compared to a placebo and other non-steroidal anti-inflammatory drugs (NSAIDs). Methods. A systematic review of randomized, controlled trials (RCTs) of etoricoxib were performed. Bayesian network meta-analysis was used over a duration of 12 weeks. The incidence of CV and GI events for a duration ≥26 weeks were also tabulated and presented using descriptive statistics. Results. From this search, 10 studies were identified. Of these, 6 and 5 RCTs that measured the CV and GI events at 12 weeks were included in meta-analysis. They showed that etoricoxib did not increase the CV events compared to the placebo or NSAIDs during the 12 week period (odds ratio [OR]=0.59 compared to celecoxib, OR=0.89 with ibuprofen, OR=0.70 with placebo, and OR=2.16 with naproxen). The risk of GI events was comparable to that of most comparators, with the exception of naproxen, which had a significantly lower risk of GI events (OR=0.18) during the 12 week period. For a duration ≥26 weeks, the incidence of CV and GI events with etoricoxib increased with increasing duration. Conclusion. Etoricoxib is an alternative short-term treatment option for OA, showing comparable CV and GI complications to other NSAIDs. Nevertheless, further studies will be needed to elucidate the long-term safety of etoricoxib in the treatment of OA. (J Rheum Dis 2017;24:293-302)

show abstract

A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis

Abstract: Treatment with etoricoxib 30 mg q.d. provides superior efficacy vs placebo and comparable clinical efficacy vs ibuprofen 2400 mg (800 mg t.i.d.) for the treatment of OA of the hip and knee.

Cited by 52 publications

References 35 publications

Evaluation of the Dose Range of Etoricoxib in an Acute Pain Setting Using the Postoperative Dental Pain Model

Evaluation of the Dose Range of Etoricoxib in an Acute Pain Setting Using the Postoperative Dental Pain Model

Analysis of the influence of pharmacotherapy on the quality of life of seniors with osteoarthritis

Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis

Contact Info

Product

Resources

About